What question did this study set out to answer?

This study aims to evaluate how clinical and genetic variables impact esketamine response in treatment-resistant depression.

Pilot study on esketamine response in treatment-resistant depression: impact of pharmacogenetic, clinical, and demographic variables

View Full Paper

Ask AI

Bookmark

Authors

Pilot study evaluates factors affecting esketamine response in treatment-resistant depression, suggesting a multidimensional treatment approach.

This study aims to evaluate how clinical and genetic variables impact esketamine response in treatment-resistant depression.
32 patients with treatment-resistant depression received intranasal esketamine for 2 months (12 administrations)
Patients underwent pharmacogenetic testing to assess genetic variations
Responses and remission rates were analyzed in relation to clinical and genetic variables.
No single variable reliably predicted treatment response.
Adjunctive psychotherapy was significantly associated with remission rates.
Exploratory analyses indicated metabolic phenotype and pharmacotherapy may influence treatment response.

Krivosova et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Pilot study evaluates factors affecting esketamine response in treatment-resistant depression, suggesting a multidimensional treatment approach.